Evert Schimmelpennink Buys Shares in Contineum Therapeutics
Evert Schimmelpennink purchased 19,000 shares of Contineum Therapeutics on June 26, 2026.
Key Points
- Evert Schimmelpennink bought 19,000 shares of Contineum Therapeutics, Inc. on June 26, 2026.
- Contineum Therapeutics' stock traded around $13.36 with a market cap of about $530.5 million.
- Analysts have set a consensus target price of $22.33 with a 'strong buy' recommendation.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evert Schimmelpennink, a key figure at Contineum Therapeutics, Inc., purchased 19,000 shares of the company on June 26, 2026. This transaction was not made under a pre-planned trading arrangement.
Other Institutional Activity in Contineum Therapeutics
While Schimmelpennink made his move, other institutional investors also adjusted their positions in Contineum Therapeutics. Janus Henderson Group PLC increased its stake by 285,857 shares, bringing its total to 2,734,836 shares valued at approximately $35.6 million, marking an 11.7% increase. Conversely, Franklin Resources Inc. reduced its holdings by 40,140 shares, now holding 1,839,227 shares worth about $24 million, a 2.1% decrease. Millennium Management LLC made a significant addition of 704,762 shares, boosting its stake by 84.8% to 1,535,449 shares valued at $20 million.
Contineum Therapeutics, Inc. Stock Down 16.8%
Shares of NasdaqGS:CTNM traded near $13.36 on Saturday. Contineum Therapeutics has a market cap of roughly $530.5 million. The company isn't currently profitable, thus it has no meaningful P/E ratio. The stock has a 52-week range between $3.72 and $16.33. It has a 50-day moving average of $13.02 and a 200-day moving average of $12.53. The company boasts a strong current ratio of 38.0 and a quick ratio of 37.0, with a debt-to-equity ratio of 2.78.
$CTNM stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained its 'hold' rating on the stock with a price target of $16.0. Earlier in the year, on March 6, Baird reiterated a 'buy' rating with a target of $20.0. The consensus among six analysts is a 'strong buy' with an average target price of $22.33.
About Contineum Therapeutics
Contineum Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing small molecule therapies targeting neuroscience, inflammation, and immunology. Its leading product, PIPE-791, aims to treat idiopathic pulmonary fibrosis and chronic pain. The company, led by CEO Carmine N. Stengone, employs 51 people and continues to advance its clinical stage projects.
Bottom Line
Evert Schimmelpennink's purchase of shares in Contineum Therapeutics underscores ongoing insider interest in the company's potential. Investors often track insider transactions for insights into company confidence. It's important to remember that this information is backward-looking and may not reflect the current insider stance.
Get Contineum Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CTNM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.